Recurrent gene fusions in prostate cancer
10.1038/nrc2402
Crossref journal-article
Springer Science and Business Media LLC
Nature Reviews Cancer (297)
Bibliography

Kumar-Sinha, C., Tomlins, S. A., & Chinnaiyan, A. M. (2008). Recurrent gene fusions in prostate cancer. Nature Reviews Cancer, 8(7), 497–511.

Authors 3
  1. Chandan Kumar-Sinha (first)
  2. Scott A. Tomlins (additional)
  3. Arul M. Chinnaiyan (additional)
References 124 Referenced 570
  1. American Cancer Society: Cancer Facts & Figures 2007 [online] (2007).
  2. Lilja, H., Ulmert, D. & Vickers, A. J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature Rev. Cancer 8, 268–278 (2008). (10.1038/nrc2351) / Nature Rev. Cancer by H Lilja (2008)
  3. Denmeade, S. R. & Isaacs, J. T. A history of prostate cancer treatment. Nature Rev. Cancer 2, 389–396 (2002). (10.1038/nrc801) / Nature Rev. Cancer by SR Denmeade (2002)
  4. Loeb, S. & Catalona, W. J. Prostate-specific antigen in clinical practice. Cancer Lett. 249, 30–39 (2007). (10.1016/j.canlet.2006.12.022) / Cancer Lett. by S Loeb (2007)
  5. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644–648 (2005). This manuscript reported the discovery of recurrent gene fusions in a majority of prostate cancers. (10.1126/science.1117679) / Science by SA Tomlins (2005)
  6. Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177–183 (2004). (10.1038/nrc1299) / Nature Rev. Cancer by PA Futreal (2004)
  7. Ren, R. Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia. Nature Rev. Cancer 5, 172–183 (2005). (10.1038/nrc1567) / Nature Rev. Cancer by R Ren (2005)
  8. Goldman, J. M. & Melo, J. V. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451–1464 (2003). (10.1056/NEJMra020777) / N. Engl. J. Med. by JM Goldman (2003)
  9. Nowell, P. C. & Hungerford, D. A. Chromosome studies on normal and leukemic human leukocytes. J. Natl Cancer Inst. 25, 85–109 (1960). / J. Natl Cancer Inst. by PC Nowell (1960)
  10. Nowell, P. C. & Hungerford, D. A. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J. Natl Cancer Inst. 27, 1013–1035 (1961). References 9 & 10 were the first reports of the association between a chromosomal aberration (Philadelphia chromosome) and a malignancy (CML). / J. Natl Cancer Inst. by PC Nowell (1961)
  11. Rowley, J. D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290–293 (1973). (10.1038/243290a0) / Nature by JD Rowley (1973)
  12. Rowley, J. D. Chromosome translocations: dangerous liaisons revisited. Nature Rev. Cancer 1, 245–250 (2001). (10.1038/35106108) / Nature Rev. Cancer by JD Rowley (2001)
  13. Druker, B. J. et al. Activity of a specific inhibitor of the BCR–ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042 (2001). (10.1056/NEJM200104053441402) / N. Engl. J. Med. by BJ Druker (2001)
  14. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001). References 13 and 14 established Gleevec/imatinib as a specific inhibitor of BCR–ABL1 in CML. (10.1056/NEJM200104053441401) / N. Engl. J. Med. by BJ Druker (2001)
  15. Mitelman, F., Mertens, F. & Johansson, B. Prevalence estimates of recurrent balanced cytogenetic aberrations and gene fusions in unselected patients with neoplastic disorders. Genes Chromosomes Cancer 43, 350–366 (2005). (10.1002/gcc.20212) / Genes Chromosomes Cancer by F Mitelman (2005)
  16. Kumar-Sinha, C., Tomlins, S. A. & Chinnaiyan, A. M. Evidence of recurrent gene fusions in common epithelial tumors. Trends Mol. Med. (2006). (10.1016/j.molmed.2006.09.005)
  17. Mitelman, F. Recurrent chromosome aberrations in cancer. Mutat. Res. 462, 247–253 (2000). (10.1016/S1383-5742(00)00006-5) / Mutat. Res. by F Mitelman (2000)
  18. Mitelman, F., Johansson, B., Mandahl, N. & Mertens, F. Clinical significance of cytogenetic findings in solid tumors. Cancer Genet. Cytogenet. 95, 1–8 (1997). (10.1016/S0165-4608(96)00252-X) / Cancer Genet. Cytogenet. by F Mitelman (1997)
  19. Mitelman, F., Johansson, B. & Mertens, F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nature Genet. 36, 331–334 (2004). Based on an analysis of prevalence of gene fusions across all cancer types, the authors observed: “Our results support the unorthodox concept that cytogenetic aberrations resulting in deregulated or rearranged genes may be of greater importance as an initial step in epithelial tumorigenesis than generally believed.” (10.1038/ng1335) / Nature Genet. by F Mitelman (2004)
  20. Narod, S. A. & Foulkes, W. D. BRCA1 and BRCA2: 1994 and beyond. Nature Rev. Cancer 4, 665–676 (2004). (10.1038/nrc1431) / Nature Rev. Cancer by SA Narod (2004)
  21. Jeter, J. M., Kohlmann, W. & Gruber, S. B. Genetics of colorectal cancer. Oncology (Williston Park) 20, 269–276; discussion 285–286, 288–289 (2006). / Oncology (Williston Park) by JM Jeter (2006)
  22. Rowley, P. T. Inherited susceptibility to colorectal cancer. Annu. Rev. Med. 56, 539–554 (2005). (10.1146/annurev.med.56.061704.135235) / Annu. Rev. Med. by PT Rowley (2005)
  23. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004). (10.1056/NEJMoa040938) / N. Engl. J. Med. by TJ Lynch (2004)
  24. Rhodes, D. R. et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 9, 443–454 (2007). (10.1593/neo.07292) / Neoplasia by DR Rhodes (2007)
  25. Rhodes, D. R. et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9, 166–180 (2007). (10.1593/neo.07112) / Neoplasia by DR Rhodes (2007)
  26. Rhodes, D. R. et al. Mining for regulatory programs in the cancer transcriptome. Nature Genet. 37, 579–583 (2005). (10.1038/ng1578) / Nature Genet. by DR Rhodes (2005)
  27. Rhodes, D. R. et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1–6 (2004). (10.1016/S1476-5586(04)80047-2) / Neoplasia by DR Rhodes (2004)
  28. Oikawa, T. & Yamada, T. Molecular biology of the Ets family of transcription factors. Gene 303, 11–34 (2003). (10.1016/S0378-1119(02)01156-3) / Gene by T Oikawa (2003)
  29. Sorensen, P. H. et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nature Genet. 6, 146–151 (1994). (10.1038/ng0294-146) / Nature Genet. by PH Sorensen (1994)
  30. Adams, J. M. et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318, 533–538 (1985). (10.1038/318533a0) / Nature by JM Adams (1985)
  31. Taub, R. et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl Acad. Sci. USA 79, 7837–7841 (1982). (10.1073/pnas.79.24.7837) / Proc. Natl Acad. Sci. USA by R Taub (1982)
  32. Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C. & Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 226, 1097–1099 (1984). (10.1126/science.6093263) / Science by Y Tsujimoto (1984)
  33. Tomlins, S. A. et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595–599 (2007). This paper reported four novel classes of Ets gene fusions in prostate cancer, besides TMPRSS2 , indicating a complex texture of gene fusions in solid cancers (10.1038/nature06024) / Nature by SA Tomlins (2007)
  34. Tomlins, S. A. et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res. 66, 3396–3400 (2006). (10.1158/0008-5472.CAN-06-0168) / Cancer Res. by SA Tomlins (2006)
  35. Helgeson, B. E. et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res. 68, 73–80 (2008). (10.1158/0008-5472.CAN-07-5352) / Cancer Res. by BE Helgeson (2008)
  36. Hermans, K. G. et al. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res. 68, 3094–3098 (2008). (10.1158/0008-5472.CAN-08-0198) / Cancer Res. by KG Hermans (2008)
  37. MacDonald, J. W. & Ghosh, D. COPA—cancer outlier profile analysis. Bioinformatics 22, 2950–2951 (2006). (10.1093/bioinformatics/btl433) / Bioinformatics by JW MacDonald (2006)
  38. Tibshirani, R. & Hastie, T. Outlier sums for differential gene expression analysis. Biostatistics 8, 2–8 (2007). (10.1093/biostatistics/kxl005) / Biostatistics by R Tibshirani (2007)
  39. Annunziata, C. M. et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12, 115–130 (2007). (10.1016/j.ccr.2007.07.004) / Cancer Cell by CM Annunziata (2007)
  40. Demichelis, F. et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26, 4596–4599 (2007). (10.1038/sj.onc.1210237) / Oncogene by F Demichelis (2007)
  41. Cerveira, N. et al. TMPRSS2–ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8, 826–832 (2006). (10.1593/neo.06427) / Neoplasia by N Cerveira (2006)
  42. Clark, J. et al. Diversity of TMPRSS2–ERG fusion transcripts in the human prostate. Oncogene 26, 2667–2673 (2007). (10.1038/sj.onc.1210070) / Oncogene by J Clark (2007)
  43. Perner, S. et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 66, 8337–8341 (2006). (10.1158/0008-5472.CAN-06-1482) / Cancer Res. by S Perner (2006)
  44. Perner, S. et al. TMPRSS2–ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 31, 882–888 (2007). (10.1097/01.pas.0000213424.38503.aa) / Am. J. Surg. Pathol. by S Perner (2007)
  45. Mehra, R. et al. Characterization of TMPRSS2–ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 68, 3584–3590 (2008). (10.1158/0008-5472.CAN-07-6154) / Cancer Res. by R Mehra (2008)
  46. Hermans, K. G. et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 66, 10658–10663 (2006). (10.1158/0008-5472.CAN-06-1871) / Cancer Res. by KG Hermans (2006)
  47. Iljin, K. et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res. 66, 10242–10246 (2006). (10.1158/0008-5472.CAN-06-1986) / Cancer Res. by K Iljin (2006)
  48. Lapointe, J. et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod. Pathol. 20, 467–473 (2007). (10.1038/modpathol.3800759) / Mod. Pathol. by J Lapointe (2007)
  49. Rajput, A. B. et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J. Clin. Pathol. 60, 1238–1243 (2007). (10.1136/jcp.2006.043810) / J. Clin. Pathol. by AB Rajput (2007)
  50. Soller, M. J. et al. Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer. Genes Chromosomes Cancer 45, 717–719 (2006). (10.1002/gcc.20329) / Genes Chromosomes Cancer by MJ Soller (2006)
  51. Yoshimoto, M. et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 8, 465–469 (2006). (10.1593/neo.06283) / Neoplasia by M Yoshimoto (2006)
  52. Wang, J., Cai, Y., Ren, C. & Ittmann, M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res. 66, 8347–8351 (2006). (10.1158/0008-5472.CAN-06-1966) / Cancer Res. by J Wang (2006)
  53. Liu, W. et al. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer 46, 972–980 (2007). (10.1002/gcc.20482) / Genes Chromosomes Cancer by W Liu (2007)
  54. Melo, J. V. The diversity of BCR–ABL fusion proteins and their relationship to leukemia phenotype. Blood 88, 2375–2384 (1996). (10.1182/blood.V88.7.2375.bloodjournal8872375) / Blood by JV Melo (1996)
  55. Lynch, H. T., Smyrk, T. & Lynch, J. F. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch Syndrome). Int. J. Cancer 69, 38–43 (1996). (10.1002/(SICI)1097-0215(19960220)69:1<38::AID-IJC9>3.0.CO;2-X) / Int. J. Cancer by HT Lynch (1996)
  56. Halvarsson, B. et al. Phenotypic heterogeneity in hereditary non-polyposis colorectal cancer: identical germline mutations associated with variable tumour morphology and immunohistochemical expression. J. Clin. Pathol. 60, 781–786 (2007). (10.1136/jcp.2006.040402) / J. Clin. Pathol. by B Halvarsson (2007)
  57. Lakhani, S. R. et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl Cancer Inst. 90, 1138–1145 (1998). (10.1093/jnci/90.15.1138) / J. Natl Cancer Inst. by SR Lakhani (1998)
  58. Lakhani, S. R. The pathology of familial breast cancer: Morphological aspects. Breast Cancer Res. 1, 31–35 (1999). (10.1186/bcr10) / Breast Cancer Res. by SR Lakhani (1999)
  59. Mosquera, J. M. et al. Morphological features of TMPRSS2–ERG gene fusion prostate cancer. J. Pathol. 212, 91–101 (2007). (10.1002/path.2154) / J. Pathol. by JM Mosquera (2007)
  60. Tu, J. J. et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod. Pathol. 20, 921–928 (2007). (10.1038/modpathol.3800903) / Mod. Pathol. by JJ Tu (2007)
  61. Mehra, R. et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod. Pathol. 20, 538–544 (2007). (10.1038/modpathol.3800769) / Mod. Pathol. by R Mehra (2007)
  62. Nami, R. K. et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol. Ther. 6, 40–45 (2007). (10.4161/cbt.6.1.3489) / Cancer Biol. Ther. by RK Nami (2007)
  63. Nam, R. K. et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br. J. Cancer 97, 1690–1695 (2007). (10.1038/sj.bjc.6604054) / Br. J. Cancer by RK Nam (2007)
  64. Attard, G. et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 27, 253–263 (2007). This paper analysed the prognosis of prostate cancer patients with respect to their TMPRSS2 – ERG rearrangement status and concluded that duplication of the fusion is associated with very poor cause-specific survival (25% survival at 8 years) compared with ERG rearrangement-negative cases (90% survival at 8 years). / Oncogene by G Attard (2007)
  65. Petrovics, G. et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 24, 3847–3852 (2005). (10.1038/sj.onc.1208518) / Oncogene by G Petrovics (2005)
  66. Winnes, M., Lissbrant, E., Damber, J. E. & Stenman, G. Molecular genetic analyses of the TMPRSS2–ERG and TMPRSS2–ETV1 gene fusions in 50 cases of prostate cancer. Oncol. Rep. 17, 1033–1036 (2007). / Oncol. Rep. by M Winnes (2007)
  67. Arora, R. et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100, 2362–2366 (2004). (10.1002/cncr.20243) / Cancer by R Arora (2004)
  68. Mehra, R. et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 67, 7991–7995 (2007). (10.1158/0008-5472.CAN-07-2043) / Cancer Res. by R Mehra (2007)
  69. Barry, M., Perner, S., Demichelis, F. & Rubin, M. A. TMPRSS2–ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 70, 630–633 (2007). (10.1016/j.urology.2007.08.032) / Urology by M Barry (2007)
  70. Clark, J. et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 27, 1993–2003 (2008). (10.1038/sj.onc.1210843) / Oncogene by J Clark (2008)
  71. Mehra, R. et al. Characterization of TMPRSS2–ETS gene aberrations in androgen independent metastatic prostate cancer. Cancer Res. 68, 3584–3590 (2008). (10.1158/0008-5472.CAN-07-6154) / Cancer Res. by R Mehra (2008)
  72. Skoda, R. & Prchal, J. T. Lessons from familial myeloproliferative disorders. Semin. Hematol. 42, 266–273 (2005). (10.1053/j.seminhematol.2005.08.002) / Semin. Hematol. by R Skoda (2005)
  73. Langeberg, W. J., Isaacs, W. B. & Stanford, J. L. Genetic etiology of hereditary prostate cancer. Front. Biosci. 12, 4101–4110 (2007). (10.2741/2374) / Front. Biosci. by WJ Langeberg (2007)
  74. Setlur, S. R. et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J. Natl Cancer Inst. 100, 915–925 (2008). (10.1093/jnci/djn150) / J. Natl Cancer Inst. by SR Setlur (2008)
  75. Bonkhoff, H., Fixemer, T., Hunsicker, I. & Remberger, K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am. J. Pathol. 155, 641–647 (1999). (10.1016/S0002-9440(10)65160-7) / Am. J. Pathol. by H Bonkhoff (1999)
  76. Glinsky, G. V., Glinskii, A. B., Stephenson, A. J., Hoffman, R. M. & Gerald, W. L. Gene expression profiling predicts clinical outcome of prostate cancer. J. Clin. Invest. 113, 913–923 (2004). (10.1172/JCI20032) / J. Clin. Invest. by GV Glinsky (2004)
  77. Tomlins, S. A. et al. Integrative molecular concept modeling of prostate cancer progression. Nature Genet. 39, 41–51 (2007). (10.1038/ng1935) / Nature Genet. by SA Tomlins (2007)
  78. Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl Acad. Sci. USA 101, 811–816 (2004). (10.1073/pnas.0304146101) / Proc. Natl Acad. Sci. USA by J Lapointe (2004)
  79. Kim, J. H. et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res. 67, 8229–8239 (2007). (10.1158/0008-5472.CAN-07-1297) / Cancer Res. by JH Kim (2007)
  80. Lapointe, J. et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 67, 8504–8510 (2007). (10.1158/0008-5472.CAN-07-0673) / Cancer Res. by J Lapointe (2007)
  81. Lin, B. et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 59, 4180–4184 (1999). / Cancer Res. by B Lin (1999)
  82. Afar, D. E. et al. Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer Res. 61, 1686–1692 (2001). / Cancer Res. by DE Afar (2001)
  83. Vaarala, M. H., Porvari, K., Kyllonen, A., Lukkarinen, O. & Vihko, P. The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease. Int. J. Cancer 94, 705–710 (2001). (10.1002/ijc.1526) / Int. J. Cancer by MH Vaarala (2001)
  84. Mertz, K. D. et al. Molecular characterization of TMPRSS2–ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 9, 200–206 (2007). (10.1593/neo.07103) / Neoplasia by KD Mertz (2007)
  85. Cai, C. et al. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol. Endocrinol. 21, 1835–1846 (2007). (10.1210/me.2006-0480) / Mol. Endocrinol. by C Cai (2007)
  86. Ellwood-Yen, K. et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223–238 (2003). (10.1016/S1535-6108(03)00197-1) / Cancer Cell by K Ellwood-Yen (2003)
  87. Tomlins, S. A. et al. Role of the TMPRSS2–ERG gene fusion in prostate cancer. Neoplasia 10, 177–188 (2008). (10.1593/neo.07822) / Neoplasia by SA Tomlins (2008)
  88. Klezovitch, O. et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl Acad. Sci. USA 105, 2105–2110 (2008). (10.1073/pnas.0711711105) / Proc. Natl Acad. Sci. USA by O Klezovitch (2008)
  89. Klezovitch, O. et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc. Natl Acad. Sci USA 105, 2105–2110 (2008). (10.1073/pnas.0711711105) / Proc. Natl Acad. Sci USA by O Klezovitch (2008)
  90. Shaffer, D. R. & Pandolfi, P. P. Breaking the rules of cancer. Nature Med. 12, 14–15 (2006). (10.1038/nm0106-14) / Nature Med. by DR Shaffer (2006)
  91. Crawford, E. D. PSA testing: what is the use? Lancet 365, 1447–1449 (10.1016/S0140-6736(05)66398-2)
  92. Stamey, T. A. et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J. Urol. 172, 1297–1301 (2004). (10.1097/01.ju.0000139993.51181.5d) / J. Urol. by TA Stamey (2004)
  93. Frankel, S., Smith, G. D., Donovan, J. & Neal, D. Screening for prostate cancer. Lancet 361, 1122–1128 (2003). (10.1016/S0140-6736(03)12890-5) / Lancet by S Frankel (2003)
  94. Mao, X. et al. Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian J. Androl. 10, 467–473 (2008). (10.1111/j.1745-7262.2008.00401.x) / Asian J. Androl. by X Mao (2008)
  95. Laxman, B. et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 8, 885–888 (2006). (10.1593/neo.06625) / Neoplasia by B Laxman (2006)
  96. Laxman, B. et al. A first generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res. 68, 645–649 (2007). (10.1158/0008-5472.CAN-07-3224) / Cancer Res. by B Laxman (2007)
  97. Hessels, D. et al. Detection of TMPRSS2–ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin. Cancer Res. 13, 5103–5108 (2007). (10.1158/1078-0432.CCR-07-0700) / Clin. Cancer Res. by D Hessels (2007)
  98. Huggins, C. & Hodges, C. V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 5 (1941). / Cancer Res. by C Huggins (1941)
  99. Huggins, C., Stevens, R. E. & Hodges, C. V. Studies on prostatic cancer: 2. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43 209–222 (1941). References 98 and 99 mark the pioneering work of C. Huggins and C. V. Hodges that introduced androgen ablation therapy as a treatment modality for prostate cancer. (10.1001/archsurg.1941.01210140043004) / Arch. Surg. by C Huggins (1941)
  100. Schally, A. V., Kastin, A. J. & Arimura, A. Hypothalamic FSH and LH-regulating hormone. Structure, physiology and clinical studies. Fertil. Steril. 22, 703–721 (1971). (10.1016/S0015-0282(16)38580-6) / Fertil. Steril. by AV Schally (1971)
  101. Denmeade, S. R. & Isaacs, J. T. in Cancer Medicine 5th edn (eds Bast, R. C. et al.) 765–776 (B. C. Decker, Hamilton, Ontario, 2000). / Cancer Medicine by SR Denmeade (2000)
  102. Steinberg, G. D. & Isaacs, J. T. in Cancer Chemotherapy (eds Hickman, J. A. & Hitton, T. R.) 322–341 (Blackwell Scientific Publications, Oxford, 1993). / Cancer Chemotherapy by GD Steinberg (1993)
  103. Varenhorst, E., Wallentin, L. & Carlstrom, K. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. Scand. J. Urol. Nephrol. 16, 31–36 (1982). (10.3109/00365598209179637) / Scand. J. Urol. Nephrol. by E Varenhorst (1982)
  104. Liao, S., Howell, D. K. & Chang, T. M. Action of a nonsteroidal antiandrogen, flutamide, on the receptor binding and nuclear retention of 5 α-dihydrotestosterone in rat ventral prostate. Endocrinology 94, 1205–1209 (1974). (10.1210/endo-94-4-1205) / Endocrinology by S Liao (1974)
  105. Maximum androgen blockage in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346, 265–269 (1995). (10.1016/S0140-6736(95)92163-X)
  106. Laufer, M., Denmeade, S. R., Sinibaldi, V., Carducci, M. & Eisenberger, M. A. Complete androgen blockade for prostate cancer: What went wrong? J. Urol. 164, 3–9 (2000). (10.1016/S0022-5347(05)67436-8) / J. Urol. by M Laufer (2000)
  107. Soda, M. et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007). The first report of a recurrent gene fusion in lung cancer. (10.1038/nature05945) / Nature by M Soda (2007)
  108. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 14 (2007). (10.1016/j.cell.2007.11.025) / Cell by K Rikova (2007)
  109. Korbel, J. O. et al. Paired-end mapping reveals extensive structural variation in the human genome. Science 318, 420–426 (2007). (10.1126/science.1149504) / Science by JO Korbel (2007)
  110. Ruan, Y. et al. Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs). Genome Res. 17, 828–838 (2007). (10.1101/gr.6018607) / Genome Res. by Y Ruan (2007)
  111. Rabbitts, T. H. Chromosomal translocations in human cancer. Nature 372, 143–149 (1994). (10.1038/372143a0) / Nature by TH Rabbitts (1994)
  112. Gleissner, B. et al. Leading prognostic relevance of the BCR–ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99, 1536–1543 (2002). (10.1182/blood.V99.5.1536) / Blood by B Gleissner (2002)
  113. Ribeiro, R. C. et al. Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood 70, 948–953 (1987). (10.1182/blood.V70.4.948.948) / Blood by RC Ribeiro (1987)
  114. Nowell, P. C. & Hungerford, D. A. A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497–1501 (1960). / Science by PC Nowell (1960)
  115. Hughes, T. et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108, 28–37 (2006). (10.1182/blood-2006-01-0092) / Blood by T Hughes (2006)
  116. Lugo, T. G., Pendergast, A. M., Muller, A. J. & Witte, O. N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247, 1079–1082 (1990). (10.1126/science.2408149) / Science by TG Lugo (1990)
  117. Daley, G. Q., Van Etten, R. A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824–830 (1990). (10.1126/science.2406902) / Science by GQ Daley (1990)
  118. Elefanty, A. G., Hariharan, I. K. & Cory, S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 9, 1069–1078 (1990). (10.1002/j.1460-2075.1990.tb08212.x) / EMBO J. by AG Elefanty (1990)
  119. Kelliher, M. A., McLaughlin, J., Witte, O. N. & Rosenberg, N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl Acad. Sci. USA 87, 6649–6653 (1990). (10.1073/pnas.87.17.6649) / Proc. Natl Acad. Sci. USA by MA Kelliher (1990)
  120. Koschmieder, S. et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR–ABL leukemogenesis. Blood 105, 324–334 (2005). (10.1182/blood-2003-12-4369) / Blood by S Koschmieder (2005)
  121. Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408–2417 (2006). (10.1056/NEJMoa062867) / N. Engl. J. Med. by BJ Druker (2006)
  122. Hughes, T. P. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423–1432 (2003). (10.1056/NEJMoa030513) / N. Engl. J. Med. by TP Hughes (2003)
  123. O'Brien, S. G. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994–1004 (2003). (10.1056/NEJMoa022457) / N. Engl. J. Med. by SG O'Brien (2003)
  124. Jhavar, S. et al. Detection of TMPRSS2–ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. J. Mol. Diagn. 10, 50–57 (2008). (10.2353/jmoldx.2008.070085) / J. Mol. Diagn. by S Jhavar (2008)
Dates
Type When
Created 17 years, 2 months ago (June 19, 2008, 6:52 a.m.)
Deposited 2 years, 3 months ago (May 18, 2023, 11:24 p.m.)
Indexed 1 day, 20 hours ago (Aug. 27, 2025, 12:38 p.m.)
Issued 17 years, 2 months ago (June 19, 2008)
Published 17 years, 2 months ago (June 19, 2008)
Published Online 17 years, 2 months ago (June 19, 2008)
Published Print 17 years, 1 month ago (July 1, 2008)
Funders 0

None

@article{Kumar_Sinha_2008, title={Recurrent gene fusions in prostate cancer}, volume={8}, ISSN={1474-1768}, url={http://dx.doi.org/10.1038/nrc2402}, DOI={10.1038/nrc2402}, number={7}, journal={Nature Reviews Cancer}, publisher={Springer Science and Business Media LLC}, author={Kumar-Sinha, Chandan and Tomlins, Scott A. and Chinnaiyan, Arul M.}, year={2008}, month=jun, pages={497–511} }